What question did this study set out to answer?

To examine the recent advancements in incretin biology and their therapeutic implications for type 2 diabetes.

April 5, 2026Open Access

Recent advances in incretin biology and therapeutics: From glucose‐dependent insulinotropic polypeptide reappraisal to next‐generation agonists

Key Points

To examine the recent advancements in incretin biology and their therapeutic implications for type 2 diabetes.
Review of existing literature on incretin physiology and therapeutic strategies.
Analysis of advancements in multi-receptor agonist designs.
Discussion on oral drug development and mechanistic insights into GIP physiology.
Highlighting the integrated enteroinsular network model for incretins.
Identifying multi-receptor agonism as a promising strategy for diabetes management.
Emphasizing the importance of oral drug formulations in incretin therapies.

Abstract

Future directions in incretin research: Three major directions currently shape therapeutic innovation in incretin research: multi-receptor agonism, oral drug development, and mechanistic reappraisal of glucose-dependent insulinotropic polypeptide (GIP) physiology. These advances indicate that incretin-based therapies should be understood within an integrated enteroinsular network rather than through isolated hormone actions. DPP-4, dipeptidyl peptidase-4; GCGR, glucagon receptor; GIPR, GIP receptor; GLP-1, glucagon-like peptide-1; GLP-1R, GLP-1 receptor; T2D, type 2 diabetes.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Kubota et al. (Fri,) studied this question.

synapsesocial.com/papers/69d1fdbfa79560c99a0a3fcc https://doi.org/https://doi.org/10.1111/jdi.70299

Bookmark

View Full Paper